Feb
06
Is the U.S. Government’s Sodium Reduction Policy Based Upon “The Biggest Delusion in the History of Preventive Medicine?” Strong Comments Echo Concerns of Salt Institute
Filed Under (Blood Pressure) by Content Keyword RSS

Medical researchers, business people, chefs and concerned citizens tell the FDA to drop its salt reduction scheme. The Salt Institute says the passionate response shows public wants no federal action on salt, an essential nutrient needed for good health.

(PRWeb February 01, 2012)

Read the full story at

Dec
27
Abbott rival Mylan gets FDA approval for generic hypertension drug
Filed Under (Blood Pressure) by Content Keyword RSS
(AP) — Mylan Inc. said Tuesday that the Food and Drug Administration approved the drugmaker's generic version of the high blood pressure treatment Teveten.
Dec
27
Mylan: FDA approves its generic hypertension drug
Filed Under (Blood Pressure) by Content Keyword RSS
Mylan Inc. said Tuesday that the Food and Drug Administration approved the drugmaker's generic version of the high blood pressure treatment Teveten.Teveten, or eprosartan, is marketed by Abbott Laboratories ...
Dec
27
Mylan: FDA approves its generic hypertension drug
Filed Under (Blood Pressure) by Content Keyword RSS
Mylan Inc. said Tuesday that the Food and Drug Administration approved the drugmaker's generic version of the high blood pressure treatment Teveten.
Dec
21
Takeda receives FDA approval for EDARBYCLOR to treat hypertension
Filed Under (Blood Pressure) by Content Keyword RSS
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.